Liver Lineup: GLP-1 RAs and FGF21s for MASH, with Mary Rinella, MD
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, sit down with Mary (Maru) Rinella, MD, a professor of medicine and director of Clinical Trials and the Metabolic and Fatty Liver Program at the University of Chicago, to discuss the rapidly evolving therapeutic landscape for metabolic dysfunction-associated steatohepatitis (MASH).
Key Episode Timestamps:
0:00:00 – Introduction & guest bio
0:01:02 – Current therapy landscape & GLP‑1 overview
0:03:51 – Do GLP‑1s help non–weight losers?
0:05:21 – Combining GLP‑1s and resmetirom
0:07:23 – Pipeline GLP‑1 combinations & phase 2 data
0:09:26 – Advanced disease, sarcopenia & risk–benefit in cirrhosis
0:13:29 – Introduction to FGF‑21 agonists
0:14:04 – Symmetry (efruxifermin) trial & reading the data
0:17:51 – Endpoints, “lack of progression,” and FDA hurdles
0:19:41 – Need for non‑invasive surrogates
0:21:02 – FGF‑21 mechanism & other liver diseases
0:22:57 – Alcohol intake, GLP‑1s, FGF‑21 & MetALD
0:25:49 – 10‑year outlook & future toolbox
0:27:35 – Closing